Biodue S.p.a. FY2016
BioDue S.p.A. develops, manufactures and markets cosmetics, solid and liquid food supplements and medical devices both on behalf of national and international pharmaceutical companies (Industrial division), both under its own brands (Pharcos, BiOfta and Selerbe).
In the FY2016 BioDue’s turnover increased 3.1% yoy and amounted to 34.8M€. The EBITDA (IAS principles) declined 1% yoy to 4.7M€ (13.6% EBITDA margin) and the net income amounted to 2.0M€, versus 2.4M€ of twelve months before.
Biodue SpA. BioDue SpA is an Italy-based company engaged in the healthcare industry. The Company develops, manufactures and markets cosmetics, liquid and solid food supplements, as well as medical devices on behalf of national and international pharmaceutical entities. Its activities are divided into two divisions. The Industrial division is dedicated to the production of liquid and solid food supplements, cosmetics, medical devices and herbal products, such as drops, capsules, tablets and powders, as well as skin gels and lotions, among others. The Own Brand division focuses on to the production and marketing of dermatological products, ophthalmic and food supplements, through Pharcos, Selerbe and biOfra brands.
Twice Research is an independent financial analysis company focused on Small & Medium Caps Corporate Brokerage and Investment Advisory.
Twice Research supports Top Management and the ownership of broad-listed issuers, conducting periodic studies and evaluations for internal and / or public circulation through the major domestic and international financial reporting platforms (Borsa Italiana, Thomson Reuters, Bloomberg, Factset etc.) evaluates real assets (companies, projects, intangible assets, etc.) to support investment choices of Professional Investors (Institutional and HNWI) or enhancement by the holders of such assets.
The Research Team and its partner relationships network have led Twice Research to have a privileged relationship with private investors, family office, and business angels who are particularly mindful of Small & Mid Cap investment start-ups.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.